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Alopecia areata (AA) is an organ-restricted autoim-
mune disease that mainly affects the hair follicle (HF).
Several findings support a key primary effector role of
CD8þ T cells in the disease pathogenesis. Autoreac-
tive CD8þ T cells are not only present in the char-
acteristic peribulbar inflammatory cell infiltrate of
lesional AA HFs but are also found to be infiltrating
in lesional HF epithelium where they are thought to
recognize major histocompatibility complex class
I-presented (auto-)antigens. However, the latter still
remain unidentified. Therefore, one key aim in AA
research is to identify the clonotypes of autoaggres-
sive, intralesional CD8þ T cells. Therapeutically, this is
important (a) so that these lymphocytes can be selec-
tively eliminated or inhibited, (b) to identify the—as yet
elusive—key (auto-)antigens in AA, and/or (c) to induce
peripheral tolerance against the latter. Therefore, we
have recently embarked on a National Alopecia Areata
Foundation–supported project that attempts to isolate
disease-specific, intralesional CD8þ T cells from AA
skin in order to determine their TCR clonotype, using
two complementary strategies. The first method is
based on the enzymatic skin digestion from lesional
AA skin, followed by either MACS technology and
single-cell picking or FACS cell sorting, while the
second method on laser microdissection. The identifi-
cation of disease-specific TCRs can serve as a basis for
specific AA immunotherapy along the lines sketched
above and may possibly also provide prognostic bio-
markers. If successful, this research strategy promises
to permit, at long last, the causal therapy of AA.
The Journal of Investigative Dermatology Symposium (2015) 17, 9–12;
doi:10.1038/jidsymp.2015.31
INTRODUCTION
Alopecia areata (AA) is an organ-restricted autoimmune
disorder whose pathogenesis may involve the collapse of
normal hair follicle (HF) immune privilege, a protective system
by which HFs protect themselves against autoreactive attacks
by the immune system, namely against a CD8þ T cell-driven
immune response to major histocompatibility complex (MHC)
class I-presented (auto-)antigens, helped by co-stimulatory
signals (Gilhar et al., 2012; McElwee et al., 2013; D’Ovidio,
2014; Islam et al., 2015). Given that the trigger event(s) and
the disease development are not clear yet and that the putative
autoantigen(s) still remain undefined (Gilhar et al., 2012;
McElwee et al., 2013; D’Ovidio, 2014), overall, AA therapy
remains disappointing, symptomatic, and distressing for
AA patients (Harries et al., 2010; D’Ovidio, 2014;
Falto-Aizpurua et al., 2014).
Therefore, one central challenge for current AA research is
to identify novel therapeutic targets, ideally in a manner that
improves our understanding of AA etiology and thus helps to
establish new, more efficient, better well-targeted, and ideally
causal treatment strategies.
CD8þ T cells have long been hypothesized to have a key
role in AA pathogenesis (Paus et al., 1993) and constituted a
major focus of AA research (e.g., McElwee et al., 1996; Gilhar
et al., 1998; Gilhar et al., 2012; McElwee et al., 2013; Xing
et al., 2014; Bertolini et al., 2014; Islam et al., 2015). The first
experimental evidence for the previously proposed key role of
these lymphocytes in AA induction was provided by McElwee
et al. (1996) who demonstrated that CD8þ T-cell depletion
abrogates AA onset in a rat model of AA. Shortly thereafter, a
landmark study by Gilhar et al. (1998) showed that the
transfer of CD8þ T cells alone suffices to induce AA lesions
in human scalp skin transplanted onto severe combined
immunodeficient (SCID) mice. However, maximal induction
of AA lesions in this humanized AA mouse model requires
both the help of CD4þ T cells as well as T-cell exposure
to (auto-)antigens associated with pigment-producing,
growing (i.e., anagen) HFs (Gilhar et al., 2001, 2002).
Likewise, CD8þ T cells are the key pathogenesis-initiating
immunocytes in a mouse model of AA (C3H/HeJ), yet are also
supported by CD4þ T cells (McElwee et al., 2005).
More recently, NKG2Dþ cells (most of which represent
natural killer (NK), NK T cells, and CD8þ T cells) and
NKG2D ligands like MICA were identified as novel cellular
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players in AA pathogenesis (Ito et al., 2008). This was
confirmed by a genome-wide association study that
suggested an overstimulation of CD8þ /NKG2Dþ cytotoxic
T cells by the abnormal expression of NKG2D ligands of the
MICA family (namely ULBP3) in and around lesional AA HFs
(Petukhova et al., 2010). The importance of NKG2Dþ cells
was further supported by functional evidence in a new
humanized mouse model of AA, in which the injection of
interleukin-2 stimulated NKG2Dþ /CD56þ immunocytes,
many of which are CD8þ , into healthy human skin
transplanted onto (SCID) mice induces clinical and
histopathological phenocopies of human AA lesions (Gilhar
et al., 2013a, b). Taken together, this provides strong
motivation for AA researchers to focus their attention on
intra- and perilesional CD8þ T cells.
While the specific HF (auto-)antigens recognized by auto-
reactive CD8þ T cells in patients or rodent AA models
remain to be identified, several observations suggest that they
are anagen-associated HF antigens presented by MHC class I
molecules, possibly melanogenesis-associated peptides, e.g.,
as it is primarily melanogenically active anagen III–VI HFs that
are attacked by inflammatory cell infiltrates in AA (Paus et al.,
1993; Gilhar et al., 2001; Leung et al., 2010). As the
identification of AA-specific (auto-)antigens would provide a
landmark contribution toward the development of a curative
AA treatment, the characterization of TCR clonotypes of
autoreactive, intralesional CD8þ T cells in AA lesions is a
major and critically important challenge in AA research, as
this will hopefully permit to elute relevant (auto-)antigens from
these disease-specific TCRs.
In contrast to promising, but relatively nonspecific recent AA
treatment strategies with biologicals that target CTLA-4
(Falto-Aizpurua et al., 2014), JAK pathways (Xing et al.,
2014), or tumor necrosis factor-a (Gorcey et al., 2014), the
identification of disease-specific T cells and the (auto-)antigens
will permit the development of genuinely causal AA therapy,
which selectively eliminates or functionally inhibits the
pathogenic T cells and/or induces peripheral tolerance
against the newly identified AA-associated (auto-)antigens.
METHODS
Supported by a pilot grant from National Alopecia Areata Foundation,
we have recently embarked on this methodologically challenging
exploration course by isolating and characterizing the clonotype of
CD8þ T cells directly from affected AA skin and HFs and by
reconstituting these TCRs in vitro on T–cell hybridoma line 58a-b-,
which lacks endogenous TCR a- and b-chains but carries the CD3
molecule and the machinery to produce interleukin-2 after TCR
stimulation (Seitz et al., 2006; Siewert et al., 2012), following a
basic research strategy developed by Dornmair et al. (2009). This has
already allowed to identify autoreactive TCRs in multiple sclerosis,
autoimmune myopathies and psoriasis vulgaris (Hofbauer et al., 2003;
Seitz et al., 2006; Junker et al., 2007; Kim et al., 2012), i.e., in
autoimmune disease families that show several intriguing similarities
to AA. The reconstitution of autoaggressive TCRs in vitro will enable
us to screen peptides in order to identify the elusive (auto-)antigens in
AA by using either MHC class I tetramer technology (Ito et al., 2013)
or a cDNA peptide library from AA patient (Dornmair et al., 2009).
After isolating skin- and HF-infiltrating CD8þ T cells from lesional
AA skin, single-cell reverse transcriptase–PCR is performed to pre-
amplify the TCR a- and b-chains. Successively, nested PCR and
sequencing of the PCR product is employed to identify the b-chain
and in particular the CDR3 region, which is responsible for antigen
recognition (Cole et al., 2014). To determine the matching a-chain, a
multiplex PCR and sequencing of the PCR product of the detected b-
chain-positive cells is performed by utilizing a set of universal primers
that permit unbiased amplification of any a-chain sequence (Kim
et al., 2012). To increase the chance to identify autoreactive,
intralesional CD8þ T cells, we are persuing a two-pronged
experimental strategy as described beneath, which takes into
account the fact that CD8þ T cells are not only massively
increased around the anagen bulb of lesional AA HFs, contributing
to the so-called ‘‘swarm of bees’’ infiltrate pattern, but also infiltrate
into the hair bulb epithelium, where they are thought to recognize
MHC class I-presented (auto-)antigens (Paus et al., 1993; Gilhar et al.,
2012; Bertolini et al., 2014).
Method A harvests autoreactive CD8þ T cells after enzymatic skin
digestion from lesional AA skin, followed by either MACS technology
and single-cell picking or FACS cell sorting (Weekes et al., 1999).
This technique permits fast isolation of most intracutaneous CD8þ T
cells, but does not discriminate between skin- and HF-infiltrating
CD8þ T cells and isolates not only the (very few?) antigen-specific
CD8þ T cells but also the more frequent ‘‘bystander CD8þ T cells,’’
which participate in the inflammatory response (Sharma and Thomas,
2014; Shibuya et al., 2015).
Method B uses laser microdissection to extract individual CD8þ
T cells from defined peri- and intralesional tissue compartments
(Seitz et al., 2006; Junker et al., 2007; Kim et al., 2012), here from
lesional skin of AA patients. While this method is much more
laborious, it allows one to discriminate between skin- and
HF-infiltrating CD8þ T cells and reduces the number of bystander
T cells sharply, especially if only intraepithelial CD8þ T cells are
picked.
RESULTS AND DISCUSSION
One year after having embarked onto this research project, we
have established the above methods and have been able to
characterize the first few TCR b-chains of autoreactive,
intralesional CD8þ T cells from the skin of AA patients.
However, there is still a very long way to go until disease- and
antigen-specific TCRs will have been identified, not the least
because these are expected to vary greatly from patient to
patient, but also depending on the patient’s HLA haplotype
(Bhati et al., 2014). Moreover, each AA disease stage is
characterized by a very different immunohistological and
clinical phenotype (Tosti et al., 2008; Dy and Whiting,
2011; Gilhar et al., 2012; D’Ovidio, 2014). Therefore, if the
hypothesis that AA may only represent a stereotypic response
pattern to immunologically mediated HF damage, rather than
one well-defined disease entity, whose inciting cellular
immunopathology can differ greatly between individual AA
patients and phenotypes (Paus in: McElwee et al., 2013) is
correct, the range of autoreactive T-cell clonotypes and
relevant (auto-)antigens could be much wider than expected.
To complicate matters further, for the current purpose, we
mainly require lesional AA skin in the acute or, at the most,
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subacute stage, so as to avoid later disease stages of this
autoimmune disease where epitope spreading (Shibuya et al.,
2015) is likely to have occurred; yet, unfortunately, acute AA
lesions are much more difficult to obtain than chronic ones.
Moreover, having isolated and characterized the autoreactive,
intralesional CD8þ T-cell clones of human AA skin will only
be the starting point of a long experimental journey aimed
at identifying the (auto-)antigens recognized by these
characterized TCRs, following the strategy sketched above.
CONCLUSION
Ultimately, it is expected that the identification and character-
ization of antigen-specific, intralesional CD8þ T cells from
the skin of AA patients will inform us how best to selectively
delete them from affected patients (McNally et al., 2014), or at
least to functionally inhibit them, and/or to induce peripheral
immune tolerance against the relevant (auto-)antigens (e.g., by
ex vivo generation of antigen-specific immunosuppressive
regulatory T cells (Kasagi et al., 2014)). Finally, it is also
conceivable that the identification of disease-specific TCRs
may provide prognostic biomarkers that help to predict the
expected disease progression so as to obtain objective
guidance for the choice of symptomic AA therapy (e.g.,
conventional versus biologics, mild versus aggressive), in
particular now that extremely expensive biologicals with
potentially severe adverse effects are entering the clinical
theater of AA management (Klastersky, 2014).
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